Teva Pharmaceutical Industries Ltd Stock Hold Recommendation Reiterated (TEVA)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK (TheStreet) -- Teva Pharmaceutical Industries (NYSE:TEVA) has been reiterated by TheStreet Ratings as a hold with a ratings score of C+ . The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and a generally disappointing performance in the stock itself.

• EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

Highlights from the ratings report include:

• The revenue growth came in higher than the industry average of 4.0%. Since the same quarter one year prior, revenues rose by 14.4%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
• The debt-to-equity ratio is somewhat low, currently at 0.60, and is less than that of the industry average, implying that there has been a relatively successful effort in the management of debt levels. Despite the fact that TEVA's debt-to-equity ratio is low, the quick ratio, which is currently 0.68, displays a potential problem in covering short-term cash needs.
• The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Pharmaceuticals industry. The net income has significantly decreased by 108.6% when compared to the same quarter one year ago, falling from $916.00 million to -$79.00 million.
• The company's current return on equity has slightly decreased from the same quarter one year prior. This implies a minor weakness in the organization. In comparison to the other companies in the Pharmaceuticals industry and the overall market, TEVA PHARMACEUTICALS's return on equity is significantly below that of the industry average and is below that of the S&P 500.

Teva Pharmaceutical Industries Limited develops, manufactures, and sells pharmaceutical products worldwide. Teva has a market cap of $33.2 billion and is part of the health care sector and drugs industry. The company has a P/E ratio of 10.3, below the S&P 500 P/E ratio of 17.7. Shares are up 2.8% year to date as of the close of trading on Wednesday.

You can view the full Teva Ratings Report or get investment ideas from our investment research center.

--Written by a member of TheStreet Ratings Staff.

HOLIDAY SPECIAL: Let Jim Cramer show you every trade he is making in his $2.5 Million portfolio. Join now for 14-days FREE. Sign up today to get e-mail alerts before every trade

 

For more information on Teva Pharmaceutical Industries Ltd click any of the following:

• Teva Pharmaceutical Industries Ltd Stock Price

• Teva Pharmaceutical Industries Ltd Analyst Ratings

• Teva Pharmaceutical Industries Ltd Key Stats & Profile

• Teva Pharmaceutical Industries Ltd Earnings

• Teva Pharmaceutical Industries Ltd Ratio Comparison

• Teva Pharmaceutical Industries Ltd Growth Rates

• Teva Pharmaceutical Industries Ltd Balance Sheet

• Teva Pharmaceutical Industries Ltd Cash Flow

• Teva Pharmaceutical Industries Ltd Income Statement